ALNA - オ―レナ・ファ―マシュ―ティカルズ (Allena Pharmaceuticals Inc.) オ―レナ・ファ―マシュ―ティカルズ

 ALNAのチャート


 ALNAの企業情報

symbol ALNA
会社名 Allena Pharmaceuticals Inc (オ―レナ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アレナ・ファーマスーティカルズ(Allena Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は代謝疾患および孤児性疾患を治療する非全身性経口タンパク質治療薬の開発・製品化に重点を置いて、特に腎臓および泌尿器疾患に重点を置く。リード製品候補のALLN-177は胃腸管の蓚酸塩を標的にして胃酸分泌を減少させるフェーズⅡ臨床試験中であり、高酸素尿症および腎結石の慢性管理のために開発される。ALLN-177はシュウ酸カルシウム関連の合併症の発生率を減少させ、腎臓にシュウ酸カルシウム結晶または結石として堆積するために全身的に利用可能なシュウ酸塩を減少させる可能性がある。同社の技術法は胃腸管に留まる経口タンパク質療法の設計と開発を可能にする。   オ―レナ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。子会社を通じて、腎臓に影響する代謝異常に注力した経口用酵素治療薬の開発・商用化に従事する。腎臓結石と関連する高シュウ酸尿症の治療薬「ALLN-177」は後期臨床段階である。また、慢性腎臓疾患を緩和する「ALLN-346」も開発中。本社所在地はマサチュ―セッツ州ニュ―トン。   Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study and a Phase 2a program planned for 2021.
本社所在地 One Newton Executive Park Suite 202 Newton MA 02462 USA
代表者氏名 Louis Brenner ルイス・ブレナー
代表者役職名 President Chief Operating Officer 社長兼最高執行責任者(COO)
電話番号 +1 617-467-4577
設立年月日 40695
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 37人
url www.allenapharma.com
nasdaq_url https://www.nasdaq.com/symbol/alna
adr_tso
EBITDA EBITDA(百万ドル) -26.97500
終値(lastsale) 10.28
時価総額(marketcap) 213332276.76
時価総額 時価総額(百万ドル) 215.61500
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 146.74100
当期純利益 当期純利益(百万ドル) -27.89700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Allena Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 60% to $16.5M. Higher net loss reflects Research_Development - Balancing value increase of 49% to $11.6M (expense) General and Administrative - Balancing. increase of 76% to $3.6M (expense) Stock-based Compensation in SGA increase from $139K to $682K (expense).

 ALNAのテクニカル分析


 ALNAのニュース

   Allena Revises Interim Reloxaliase Analysis Targeted Now For Q1 2022; ALLN-346 Phase 2 Data On Track For End Of 2021  2021/07/12 15:07:06 Benzinga
Allena Pharmaceuticals Inc (NASDAQ: ALNA ) provided progress updates on its ALLN-346 and reloxaliase (ALLN-177) clinical programs. ALLN-346 is an enzyme therapy for hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of uric acid. The Company recently completed a Phase 1b multiple ascending dose study. ALLN-346 was well tolerated with no evidence of systemic absorption, and no significant safety signals and serious adverse events were reported. As previously reported, the Company will initiate two Phase Full story available on Benzinga.com
   Allena Pharma provides update on clinical development programs: ALLN-346 and ALLN-177  2021/07/12 13:33:54 Seeking Alpha
   Allena Pharmaceuticals Provides Update on Clinical Development Programs  2021/07/12 12:00:00 Intrado Digital Media
-ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021-
   Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference  2021/07/08 20:17:00 Intrado Digital Media
NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Management will also be available for 1x1 meetings on July 13-14, 2021. Details for the presentation are below:
   Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/07/08 02:16:33 Stock Equity
Uber Technologies, Inc. (NYSE:UBER) with the stream of -3.15% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of -3.94% in the last hour of Wednesdays trading session. The post Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .
   Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference  2021/07/08 20:17:00 Intrado Digital Media
NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Management will also be available for 1x1 meetings on July 13-14, 2021. Details for the presentation are below:
   Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/07/08 02:16:33 Stock Equity
Uber Technologies, Inc. (NYSE:UBER) with the stream of -3.15% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of -3.94% in the last hour of Wednesdays trading session. The post Traders should follow this: Uber Technologies, Inc. (NYSE:UBER), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .
   Hot Stock in Focus: Facebook, Inc. (NASDAQ:FB), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/07/04 20:46:48 Stock Equity
Facebook, Inc. (NASDAQ:FB) with the stream of 0.09% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of 0.76% in the last hour of trading session. Facebook, Inc. The post Hot Stock in Focus: Facebook, Inc. (NASDAQ:FB), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .
   Most Recent Figure Make This Stock Even More Attractive: eBay Inc. (NASDAQ:EBAY), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/07/02 00:01:49 Stock Equity
eBay Inc. (NASDAQ:EBAY) with the stream of -0.37% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of 0.77% in the last hour of Thursdays trading session. eBay The post Most Recent Figure Make This Stock Even More Attractive: eBay Inc. (NASDAQ:EBAY), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .
   Trending Stock to Observe: Walmart Inc. (NYSE:WMT), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)  2021/06/30 01:08:00 Stock Equity
Walmart Inc. (NYSE:WMT) with the stream of -0.27% also noticed, India Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) encountered a rapid change of -0.73% in the last hour of Tuesdays trading session. Walmart The post Trending Stock to Observe: Walmart Inc. (NYSE:WMT), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .
   Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?  2020/06/02 13:31:00 PR Newswire
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs  2020/06/02 11:45:45 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aileron Therapeutics Inc (NASDAQ: ALRN ) (announced positive interim results for its Phase 1b/2 study of ALRN-6924 as an agent to protect patients against chemotherapy-induced toxicity) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cerus Corporation (NASDAQ: CERS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) (reacted to reports of partner Sinovac expressing confidence in its coronavirus vaccine) Emergent Biosolutions Inc (NYSE: EBS ) (announced $628-million dollar BARDA funding for rapid development of COVID-19 vaccine candidates) Imara Inc (NASDAQ: IMRA ) Immunovant Inc (NASDAQ: IMVT ) Inari Medical Inc (NASDAQ: NARI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) MEI Pharma Inc (NASDAQ: MEIP ) Novo Nordisk A/S (NYSE: NVO ) Protara Therapeutics Inc (NASDAQ: TARA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 1) Ocugen Inc (NASDAQ: OCGN ) (announced discontinuation of Phase 3 trial of OCU300 for ocular Graft vs.
   Allena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the Upgrade  2020/04/22 16:00:08 Zacks Investment Research
Allena Pharmaceuticals, Inc. (ALNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment  2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オ―レナ・ファ―マシュ―ティカルズ ALNA Allena Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)